United Microelectronics ADR

Geopolitical risks have increased significantly, especially with the U.S. becoming a less reliable ally under President Donald Trump's increasingly isolationist policies. UMC's exposure to AI demand remains, but the market's enthusiasm has cooled, reducing potential upside catalysts. Despite strong fundamentals like a solid dividend yield and a low price to tangible book value ratio, the stock's price support has weakened since the American election in November.» Mehr auf seekingalpha.com

TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), today reported unaudited net sales for the month of February 2025. Revenues for February 2025 Period 2025 2024 Y/Y Change Y/Y (%) February 18,193,515 17,451,268 742,247 4.25% Jan.-Feb. 38,000,310 36,464,965 1,535,345 4.21% (*) All figures in thousands of New Taiwan Dollars (NT$), except for percentages (**) All figures are consolidated Additional information about UMC is available on the web at.» Mehr auf businesswire.com

Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac disease modeling and therapeutic screening, including both drug candidates and gene editing approaches Driving Innovation: This installation paves the way for future co-development projects with UMC Utrecht, advancing human-based research and cardiac regenerative technologies BOSTON and UTRECHT, Netherlands, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, and Novoheart, its wholly owned pre-clinical subsidiary pioneering human-based cardiac tissue engineering for disease modelling and drug screening, are pleased to announce the installation of their state-of-the-art CTScreen™ platform at the University Medical Center Utrecht (UMC Utrecht). This milestone equips the Regenerative Medicine Center Utrecht with a leading-edge system to model human cardiac diseases, develop therapies, and transform preclinical cardiac research.» Mehr auf globenewswire.com